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SUMMARY
Background
The mixed l- and j-opioid receptor agonist and d-opioid receptor antagonist,
eluxadoline, is licensed in the USA for the treatment of irritable bowel syn-
drome with diarrhoea (IBS-D), based on the results of two large Phase 3 clini-
cal trials.
Aim
To understand the time course of treatment benefits with eluxadoline by com-
paring responder rates over the first month of treatment with responder rates
over longer treatment intervals.
Methods
In this post hoc analysis of two Phase 3 studies, composite and adequate relief
(AR) responder rates were calculated over month 1 and patients were stratified
by their responder status. Cumulative counts over subsequent intervals (months
1–3, months 1–6, months 2 through 6) were tallied.
Results
The studies randomised 2428 patients. Over month 1, 24.6%, 22.8% and 12.5% of
patients were composite responders with eluxadoline 100 mg, eluxadoline 75 mg
and placebo respectively. For month 1 responders, 77.8% and 81.5% (over months
1–3) and 70.7% and 73.9% (over months 1–6) showed a continuous response with
eluxadoline 100 mg and 75 mg respectively. [Correction added on 5 April 2017, after
first online publication: The percentage for the responders over months 1–3 was
previously wrong and has been corrected.] Of the month 1 nonresponders, <20%
showed a response over months 1–3 or months 1–6. Similar results were seen for the
analysis of proportions of AR responders over these time intervals.
Conclusions
Over two-thirds of patients who respond over the first month retain a positive
response over 6 months of treatment with eluxadoline, indicating that early
clinical response to eluxadoline is associated with sustained benefits for up to
6 months in patients with IBS-D.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional
gastrointestinal (GI) disorder that is characterised by
recurring abdominal pain or discomfort associated with
altered bowel habits in the absence of demonstrable
organic disease.1, 2 IBS is diagnosed using the Rome III
criteria, and can be classified into subtypes according to
the predominant stool pattern, including IBS with consti-
pation, IBS with diarrhoea (IBS-D) and IBS with mixed
bowel habits.1 It has been estimated that ~40% of IBS
cases fall into the IBS-D subtype,3 characterised by loose
or watery stools for ≥25% and hard or lumpy stools for
<25% of bowel movements;1 however, some overlap of
symptoms has been reported with functional diarrhoea.4
Irritable bowel syndrome is estimated to affect up to
20% of adults in the US population,5 is one of the most
commonly diagnosed GI disorders,6 and is associated
with higher levels of somatisation, expressed as the feel-
ing of tiredness and the experience of bloating.7 In the
majority of patients, IBS is a chronic, relapsing disease,
with a previous systematic review finding that IBS symp-
toms worsened over the course of long-term follow-up
for 2–18% of patients, and remained the same for 30–
50% of patients.8 As a result of its chronic nature, IBS is
associated with a significant economic burden and exten-
sive healthcare resource utilisation,6 as well as a marked
impact on patient health-related quality of life.9, 10
Eluxadoline is a mixed l- and j-opioid receptor ago-
nist and d-opioid receptor antagonist, approved for the
treatment of IBS-D in adults.11 Opioid receptors in the
GI tract are known to modulate gut motility and secre-
tion,12 with pre-clinical studies showing that eluxadoline
normalised disrupted GI transit over a wide dose range
in mice.13 Two large Phase 3 studies14 have demon-
strated that twice-daily treatment with eluxadoline is
effective vs. placebo in simultaneously relieving the
symptoms of abdominal pain and diarrhoea associated
with IBS-D, measured using a composite efficacy end-
point combining stool consistency and abdominal pain
responses.
Given the chronic nature of IBS-D, it is important to
clearly understand the time course of treatment benefits
seen with eluxadoline, and secondary to this, to define
the outcomes of patients who show either an initial
response or lack of response to eluxadoline treatment.
More specifically, will those who respond early continue
to respond over time, and will those who fail to respond
early on ultimately show a response with continued
treatment? These post hoc analyses of the two Phase 3
clinical studies therefore evaluated proportions of
composite responders over the first month of treatment,
compared with response rates over longer treatment
intervals. Continued efficacy with eluxadoline treatment
was also evaluated using IBS adequate relief (AR)
response rates as an alternative efficacy measure, as the
composite response rate may underestimate treatment
benefit.
METHODS
Study design
Two double-blind, placebo controlled, Phase 3 clinical
trials (IBS-3001; NCT01553591 and IBS-3002;
NCT01553747) randomised patients 1:1:1 to twice-daily
treatment with eluxadoline 100 or 75 mg or placebo.
The methodology and results of these two studies have
been described previously.14
Briefly, both studies were identical through 26 weeks
of treatment, followed by a 26-week safety assessment
and a 2-week follow-up period (IBS-3001 only) or a 4-
week single-blind placebo withdrawal period (IBS-3002
only). Enrolled participants used an electronic diary with
an interactive voice response system to record daily IBS-
D symptoms and bowel function, and weekly assess-
ments of AR through week 26.
Wherever possible, all patients withdrawing from the
studies prematurely were to undergo all end-of-treat-
ment/early withdrawal assessments. Patients who discon-
tinued participation in the studies for any reason
following randomisation were not replaced.
Patient population
Patients aged 18–80 meeting the Rome III criteria for
IBS-D1 were enrolled. Eligible patients recorded an aver-
age worst abdominal pain score >3.0 (scale of 0–10, with
0 indicating no pain, and 10 the worst imaginable pain),
an average score for stool consistency of ≥5.5 on the
Bristol Stool Form Scale (BSFS; scale of 1–7, with 1 indi-
cating hard stool, and 7 watery diarrhoea), and an aver-
age IBS-D global symptom score of ≥2.0 (scale of 0–4,
with 0 indicating no symptoms of IBS-D and 4 very
severe symptoms of IBS-D) during the week before ran-
domisation.
Patients with inflammatory bowel disease or coeliac
disease, abnormal thyroid function, history of alcohol
abuse15 or binge drinking,16 prior pancreatitis, sphincter
of Oddi dysfunction, post-cholecystectomy biliary pain,
cholecystitis in the past 6 months, intestinal obstruction,
GI infection or diverticulitis in the past 3 months were
excluded.
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Efficacy endpoints
Details and calculations for the primary endpoint have
been described previously.14 As reported by Lembo et al.,
the primary efficacy endpoint of both studies was a com-
posite response based on daily improvement of ≥30% in
worst abdominal pain score compared with average base-
line pain and, on the same day, a BSFS score of <5 on
≥50% of treatment days.14 AR response was defined by a
‘yes’ response to the following question: ‘Over the past
week, have you had AR of your IBS symptoms?’ on
≥50% of weeks. Responder rates for both the composite
endpoint and the AR endpoint were determined over the
first 3 months of treatment (weeks 1–12) and the first
6 months of treatment (weeks 1–26). Responder rates for
the composite endpoint were additionally determined
over each individual monthly interval. Monthly interval
responder rates for AR were post hoc assessments.
Data analyses
As also reported by Lembo et al., efficacy data were
pooled for the two Phase 3 studies, and analyses were
performed on the intention-to-treat (ITT) analysis set,
defined as all patients randomised to study treatment.14
No imputation for missing data was performed, as diary
compliance rules accounted for absent diary entries. For
composite response evaluations, patients were required
to have a minimum of 20 diary entries over any
monthly interval, 60 days of diary entries over the 3-
month interval and 110 days of diary entries over the
6-month interval. For AR evaluations, patients had to
have ≥6 weekly ‘yes’ responses over the 3-month inter-
val, and ≥13 weekly ‘yes’ responses over the 6-month
interval; for the post hoc AR assessment, ≥2 weekly ‘yes’
responses over any monthly interval were required.
Patients with insufficient diary data for both the com-
posite response and AR response were categorised as
nonresponders.
To assess the robustness of an early response signal,
responder rates were calculated over the first 4-week
interval (month 1) for both the composite14 and AR
(post hoc) outcome variables. Patients were stratified by
their status over month 1 (weeks 1–4), and cumulative
counts over subsequent intervals were tallied. An addi-
tional post hoc evaluation qualitatively assessed the time
to onset of treatment benefit by plotting the proportions
of patients meeting the AR response criteria for each
week over the entire 6 months of diary data collection.
A Bonferroni adjustment was taken only for the pri-
mary analyses due to two doses being studied; no further
statistical adjustments were made a priori.14 Since these
additional analyses were retrospective and the goal of
this study was to qualitatively assess treatment benefit
over time in order to offer advice to prescribers, no fur-
ther formal statistical assessments were performed,
except for the post hoc adequate relief response over the
first month to allow comparison to the previously pub-
lished composite response rates.
RESULTS
Baseline demographics and disease characteristics
A total of 2428 patients were randomised to study treat-
ment (1282 in IBS-3001; 1146 in IBS-3002). Patient base-
line and demographic characteristics were balanced
between the two studies and across treatment groups, as
previously described.14 Across both studies, there were
more female patients (IBS-3001: 65.4%; IBS-3002:
67.0%), and the mean age [standard deviation (s.d.)] was
44.9 (13.7) and 45.9 (13.5) in IBS-3001 and IBS-3002
respectively. Patients had a mean (s.d.) weekly average
BSFS score at baseline of 6.3 (0.4) and 6.2 (0.4), and a
mean (s.d.) weekly average worst abdominal pain score
of 6.2 (1.5) and 6.0 (1.5) in IBS-3001 and IBS-3002
respectively.
Proportions of responders over time
As previously reported (see figure 2 in Lembo et al.14), a
qualitative visual separation of proportions of composite
responders with both doses of eluxadoline vs. placebo
was observable within the first few days following treat-
ment initiation and reached a peak separation of ~10%
within the first 2 weeks of therapy. Once established, the
separation in responder proportions between eluxadoline
and placebo remained ~10% over the 182 days of diary
data collection.
Similarly, by day 7 (the first time point for measure-
ment of AR), separation from placebo occurred and by
day 28 (fourth AR measurement), both eluxadoline
doses reached response rates of 60%, compared to the
AR response rates of 50% seen with placebo (Figure 1).
The treatment effect then remained at ~10% over the
entire treatment period through 6 months (182 days),
and was similar between eluxadoline 100 and 75 mg
(Figure 1).
Analysis of early and sustained composite response
rates over time
In the pooled Phase 3 population, a significantly greater
proportion of patients receiving eluxadoline 100 and
75 mg were composite responders vs. placebo over the
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3-month interval (weeks 1–12) and the 6-month interval
(weeks 1–26).14 Within the pooled ITT analysis set, 765
patients (31.6%) discontinued from the studies over
weeks 1–26. Of the subjects in the treatment groups who
discontinued, 3–6% were nonresponders (Table 1).
Over month 1 (weeks 1–4), 24.6% of patients receiv-
ing eluxadoline 100 mg (P < 0.001 compared with pla-
cebo), 22.8% receiving eluxadoline 75 mg (P < 0.001
compared with placebo) and 12.5% receiving placebo
were composite responders (see the left panel of Fig-
ure 2).14 Among these patients, 77.8% treated with elux-
adoline 100 mg were also responders over the 3-month
interval (weeks 1–12), while 81.5% and 77.2% were
responders over the 3-month interval with eluxadoline
75 mg and placebo respectively. Over the longer 6-
month interval (weeks 1–26), 70.7%, 73.9% and 66.3% of
month 1 responders with eluxadoline 100 mg, eluxado-
line 75 mg and placebo, respectively, had a continuing
response. The majority of patients who were composite
responders with eluxadoline over month 1 were also
responders over the non-overlapping, distinct intervals of
month 3 (weeks 9–12) and month 6 (weeks 21–24), with
a similar sustained response observed among the month
1 placebo responders (Figure 2).
Among patients who were not composite responders
over month 1, ~10% in each treatment group became
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Figure 1 | Percentage of AR responders over 26 weeks: pooled analysis of Phase 3 studies. AR response is defined as
a ‘yes’ response to the following question: ‘Over the past week, have you had AR of your IBS symptoms?’.
AR, adequate relief; IBS, irritable bowel syndrome.
Table 1 | Proportions of composite responders among patients completing and discontinuing from the studies over
weeks 1–26: pooled Phase 3 studies
Placebo (n = 809) Eluxadoline 75 mg (n = 808) Eluxadoline 100 mg (n = 806)
Patients completing Placebo (n = 563) Eluxadoline 75 mg (n = 539) Eluxadoline 100 mg (n = 556)
Responders, n (%) 150 (26.6) 208 (38.6) 235 (42.3)
Patients discontinuing Placebo (n = 246) Eluxadoline 75 mg (n = 269) Eluxadoline 100 mg (n = 250)
Responders, n (%) 8 (3.3) 8 (3.0) 15 (6.0)
A completer is defined as a patient who either had the last day of diary data or last treatment date on or later than day 182, or
whose case record form was checked ‘Yes’ on the completion page. A discontinuer is defined as a patient whose case record
form was checked ‘No’ on the completion page. Composite response is based on daily improvement of ≥30% in worst abdominal
pain score compared with average baseline pain and, on the same day, a Bristol Stool Form Scale score of <5, on ≥50% of treat-
ment days.
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responders over the 3-month interval (weeks 1–12) (Fig-
ure 3). A slightly higher proportion of month 1 nonre-
sponders became responders over the 6-month interval
(weeks 1–26) with eluxadoline 100 mg (18.1%) com-
pared with the other treatment groups (eluxadoline
75 mg: 12.8%; placebo: 12.9%).
To further evaluate the sustainability of a monthly
response, the composite responder status over each sub-
sequent monthly interval (months 2, 3, 4, 5 and 6) was
determined for the month 1 responders. Of the patients
who were composite responders over month 1 (weeks 1–
4), 68.2% receiving eluxadoline 100 mg, 70.1% receiving
eluxadoline 75 mg and 60.4% receiving placebo showed
a sustained response over ≥3 out of any of the five
subsequent monthly intervals (Figure 4). Furthermore,
nearly half of the month 1 responders treated with elux-
adoline 100 mg (44.9%) or eluxadoline 75 mg (49.5%)
were responders for all five of the subsequent months of
treatment, with around a third of month 1 placebo
responders showing a response over all five subsequent
months.
Analysis of early and sustained AR responder rates
over time
Over month 1 (weeks 1–4), 61.8% of patients receiving
eluxadoline 100 mg (P < 0.0001 compared with pla-
cebo), 59.9% of patients receiving eluxadoline 75 mg
(P < 0.0001 compared with placebo) and 49.3% of
patients receiving placebo were AR responders (Fig-
ure 5). Of these patients, 84.1% receiving eluxadoline
100 mg had a continuing response over the 3-month
interval (weeks 1–12), while 83.7% and 82.5% of patients
receiving eluxadoline 75 mg and placebo, respectively,
were 3-month responders. Over the longer 6-month
interval (weeks 1–26), 73.1%, 70.5% and 69.7% of month
1 AR responders with eluxadoline 100 mg, eluxadoline
75 mg and placebo, respectively, had a continuing
response. The majority of patients who were AR respon-
ders with eluxadoline over month 1 were also responders
over the non-overlapping intervals of month 3 (weeks 9–
12) and month 6 (weeks 21–24) (Figure 5), with similar
findings observed for patients who were month 1 pla-
cebo responders.
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Figure 2 | Composite responders over weeks 1–4 who remained responders over weeks 1–12, weeks 1–26, weeks 9–12
and weeks 21–24: pooled analysis of Phase 3 studies. aData shown in Lembo et al.14 Composite response is based on
daily improvement of ≥30% in worst abdominal pain score compared with average baseline pain and, on the same
day, a Bristol Stool Form Scale score of <5, on ≥50% of treatment days.
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Among patients who were not AR responders over
month 1 (weeks 1–4), 10.7% receiving eluxadoline 100 mg,
15.4% receiving eluxadoline 75 mg and 11.2% receiving
placebo showed a subsequent AR response over the 3-
month interval (weeks 1–12), and 16.6% receiving elux-
adoline 100 mg, 17.0% receiving eluxadoline 75 mg and
14.6% receiving placebo showed a subsequent response
over the 6-month interval (weeks 1–26) (Figure 6).
Of the patients who showed an AR response over
month 1 (weeks 1–4), a continued response was seen for
≥3 out of any of the five subsequent months for 75.1%
receiving eluxadoline 100 mg, 71.3% receiving eluxado-
line 75 mg and 72.2% receiving placebo (Figure 7). Pro-
portions of initial responders showing sustained AR
responses over all five subsequent months were ~50% for
all treatment groups.
AR response rate among composite nonresponders
Of the patients who were not composite responders over
month 1 (weeks 1–4) (eluxadoline 100 mg: 75.4%;
eluxadoline 75 mg: 77.2%; placebo: 87.5%), ~50% did
demonstrate clinical benefit with eluxadoline based on
the AR responder endpoint over the same time period
(eluxadoline 100 mg: 51.0%; eluxadoline 75 mg: 49.5%);
proportions of responders receiving placebo were slightly
lower (43.1%) (Figure 8).
DISCUSSION
For drugs approved for continuous use to treat a chronic
illness, it is important for prescribers to understand the
potential time course of clinical benefits, including the
time to onset and the sustainability over time. Knowl-
edge about whether patients who achieve clinical benefit
early in treatment retain that response over time, and
whether patients who fail to achieve an early benefit may
develop a positive response at a later time, is critical in
establishing reasonable expectations about the effective-
ness of treatment.
Many clinical development programmes, including
eluxadoline for IBS-D, are not prospectively designed to
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nonresponders over weeks 1–4 (month 1) who became
composite responders over weeks 1–12 and 1–26:
pooled analysis of Phase 3 studies. Composite response
is based on daily improvement of ≥30% in worst
abdominal pain score compared with average baseline
pain and, on the same day, a Bristol Stool Form Scale
score of <5, on ≥50% of treatment days.
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Figure 4 | Proportions of composite responders over
weeks 1–4 (month 1) who remained responders over 3
or 5 out of the subsequent 5 months: pooled analysis of
Phase 3 studies. Composite response is based on daily
improvement of ≥30% in worst abdominal pain score
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treatment days.
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answer such questions, since the primary focus is on the
regulatory endpoint(s) necessary for approval. Because of
the waxing and waning character of IBS symptoms, it is
recommended by both the Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA)
that patient-level overall responses to IBS treatments are
determined over a specified interval (no less than
8 weeks for the FDA and 26 weeks for the EMA for
drugs intended for chronic, continuous use), with
patients required to meet the response criteria for ≥50%
of this time. Furthermore, the minimal time interval for
effectiveness has historically been no less than 4 weeks,
limiting the ability to determine time to onset of benefit.
Moreover, the regulatory endpoint of composite
response, whether analysed over 3 or 6 months, may
underestimate treatment benefit. The composite response
endpoint is based on simultaneous improvement in both
abdominal pain and stool consistency, over either the 3-
or 6-month period, resulting in an outcome measure that
may be difficult for prescribers to put into clinical con-
text. Additionally, it only assesses two IBS symptoms
and may not provide a perspective of overall patient
wellbeing and satisfaction, in contrast to a global
symptom assessment such as AR. The AR endpoint may
therefore be more relevant to the prescribing physician
and the patient, as well as being easier to comprehend;
however, it is no longer in favour from a regulatory
standpoint due to its dependence on distant patient
recall and inability to detect improvement or worsening
of specific symptoms.
As previously published, data from the two eluxado-
line Phase 3 trials demonstrated that prospectively anal-
ysed monthly assessments for the composite endpoint
were comparable to the results over the full 6 months
(weeks 1–26) of efficacy evaluation. Note that the
monthly responder rates over time in Lembo et al. are
driven by the population that met the responder criteria
at each independent monthly interval.14 In contrast, the
current analysis takes an alternative approach, assessing
only the subpopulation of patients who were responders
in the first month for a response in subsequent months.
It is important to note that for all of these analyses,
the placebo effect is prominent and the response in the
placebo arm parallels the findings in the active arms.
However, these retrospective analyses were not intended
to demonstrate separation from placebo, but rather to
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Figure 5 | AR responders over weeks 1–4 who remained responders over weeks 1–12, weeks 1–26, weeks 9–12 and
weeks 21–24: pooled analysis of Phase 3 studies. AR response is defined as a ‘yes’ response to the following question:
‘Over the past week, have you had AR of your IBS symptoms?’ AR, adequate relief; IBS, irritable bowel syndrome.
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assess how the population of patients who either did or
did not respond in month 1 fared over the remainder of
the study, independent of treatment. The similarity seen
between the active and placebo arms is not unexpected
and may be related to selection bias, since the analysis
population for continued response over subsequent
months included only month 1 responders or month 1
nonresponders.
Despite possible selection bias, these data strongly sug-
gest that the response in the placebo arm is both early
and maintained, as is true for the active treatment arms.
Factors underlying the response in the placebo arm will
also contribute in part to the response seen in the active
treatment arms. An explanation for this sustained pla-
cebo response underlying all treatment arms is unclear,
but could be related to: regression of IBS symptoms to
their respective means; the power of suggestion originat-
ing from ‘response fatigue’ or response shift due to daily
responses over 6 months to the same symptom
questions; a true physiological effect of placebo; or latent
effects unmeasured in the current studies.
Alternatively, disease variation, which again will affect
both active and placebo treatment arms, may have con-
tributed to this finding. A previous study has demon-
strated considerable variability in the natural history of
IBS, with 32–68% of patients showing an improvement
in their symptoms over the course of long-term follow-
up,8 suggesting that a degree of variation and/or
improvement in symptom severity attributable to the
underlying disease course is to be expected, regardless of
treatment arm. Similarly, it has been shown that while
62.2% of patients with IBS-D followed up for 10 months
continued to show symptoms consistent with IBS-D, the
remainder switched to the constipation subtype (7.7%),
mixed subtype (7.0%) or unspecified subtype (23.1%).17
As shown in Figure 2, regardless of treatment arm,
>65% of subjects who were composite responders within
month 1 remained responders over the full duration of
6 months (weeks 1–26), with nearly identical results seen
when evaluating the AR endpoint (Figure 5). This was
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past week, have you had AR of your IBS symptoms?’.
AR, adequate relief; IBS, irritable bowel syndrome.
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Figure 7 | Proportions of AR responders over weeks 1–
4 (month 1) who remained responders over 3 or 5 out
of the subsequent 5 months: pooled analysis of Phase
3 studies. AR response is defined as a ‘yes’ response to
the following question: ‘Over the past week, have you
had AR of your IBS symptoms?’. AR, adequate relief;
IBS, irritable bowel syndrome.
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further corroborated by the monthly assessments, which
demonstrated that >60% of subjects who showed a com-
posite response in month 1 of therapy, and ~70% who
showed an AR response, remained responders for ≥3 of
the five remaining months (Figures 4 and 7).
For those subjects who were composite nonresponders
over month 1, 18% of subjects receiving eluxadoline
100 mg were subsequent composite responders over
months 1–6 (weeks 1–26), vs. 13% for placebo (Fig-
ure 3). Similar findings were noted for the AR nonre-
sponders over month 1, whose subsequent responder
rate over months 1–6 (weeks 1–26) was ~17% for the
active arms, albeit with less prominent separation from
placebo (Figure 6).
Our results both corroborate Lembo et al.’s findings14
and demonstrate the robustness of the data. Specifically,
these analyses suggest that a response during the first
month after initiating eluxadoline treatment in IBS-D
appears to be predictive of a sustained response.
Additionally, Lembo et al. depict in their Figure 2 that
the treatment effect observed for the composite endpoint
occurred within the first few days of treatment, with the
proportion of responders on active treatment being
greater than placebo and the separation from placebo
remaining constant over the 6-month assessment per-
iod.14 A similar pattern of response over time is seen
when plotting the weekly assessments of AR response
(our Figure 1), although the ranges of response are nota-
bly higher than with the composite response.
The endpoints depicted in these two graphs are
different both from a standpoint of definition (AR for
the present Figure 1 vs. the composite endpoint of
improvement in pain and stool consistency for Lembo
et al. Figure 214) as well as the timing of assessments
(weekly for the AR endpoint with ≥50% of weeks posi-
tive and daily for the composite endpoint with ≥50% of
days positive). Both the AR and composite endpoints
qualitatively demonstrate a rapid onset that is not
detectable by assessments evaluated over 50% of a time
interval.
Based on the above, clinicians can employ both of
these endpoints despite the differing rates of response.
Therefore, the AR approach can be used, that is, a sim-
ple yes/no question, to assess response instead of the
more cumbersome composite endpoint, which requires a
daily diary record of stool consistency and pain scores.
This is critical for appreciating the benefit of eluxadoline,
as AR is an endpoint that clinicians and patients under-
stand and it can easily be adapted for day-to-day
practice.
Our data support that a trial of eluxadoline for at least
1 month to assess response is reasonable in patients with
IBS-D. Thirteen to 18% of nonresponders by either crite-
ria (composite responder or AR responder) over the first
month of treatment ultimately show a composite
response over the remaining 5 months, suggesting that
continuing therapy may offer minimal benefit to
patients. The majority of patients who respond by either
set of criteria over the first month of treatment retain
their positive response over 6 months of treatment, thus
a response in the first month bodes well for the continu-
ation of response over time.
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Figure 8 | Proportions of weeks 1–4 composite
nonresponders who were AR responders over weeks
1–4: pooled analysis of Phase 3 studies. Composite
response is based on daily improvement of ≥30% in
worst abdominal pain score compared with average
baseline pain and, on the same day, a Bristol Stool
Form Scale score of <5, on ≥50% of treatment days.
AR response is defined as a ‘yes’ response to the
following question: ‘Over the past week, have you had
AR of your IBS symptoms?’. AR, adequate relief;
IBS, irritable bowel syndrome.
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